World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01192373
Date of registration: 24/08/2010
Primary sponsor: University of Aarhus
Public title: Modulation of Free Fatty Acids in Heart Failure Patients With Diabetes: "Effect on Left Ventricular Function" Metamod3
Scientific title: Short Term Modulation of Circulating Free Fatty Acids in Heart Failure Patients With Type 2 Diabetes: "Effect on Myocardial Lipid Content, Left Ventricular Function and Exercise Capacity"
Date of first enrolment: March 2010
Target sample size: 20
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT01192373
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment  
Countries of recruitment
Denmark
Contacts
Name:   Roni R Nielsen, MD
Address: 
Telephone: 0045 5121 9363
Email: roni.r.nielse@hotmail.com
Affiliation: 
Name:   Roni R Nielsen, MD
Address: 
Telephone: 0045 5121 9363
Email: roni.r.nielsen@gmail.com
Affiliation: 
Name:   Roni R Nielsen, MD
Address: 
Telephone:
Email:
Affiliation:  Dept. of cardiolgy, Aarhus University hospital, Skejby. Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark
Key inclusion & exclusion criteria

Inclusion Criteria:

- ejection fraction at or lower than 45%

- type 2 diabetes

Exclusion Criteria:

- known s-creatinine >220mM

- known S-alanine aminotransferase >3 times normal upper limit

- other disabilitating conditions

- pregnancy

- insulin treatment



Age minimum: 30 Years
Age maximum: 85 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Diabetes
Heart Failure
Intervention(s)
Other: Metabolic substrate modulation
Primary Outcome(s)
Exercise capacity and oxygen consumption [Time Frame: 1-6 weeks]
intracellular lipid content [Time Frame: 1-6 weeks]
Left ventricular function [Time Frame: 1-6 weeks]
Secondary Outcome(s)
6 minutes hall walk test [Time Frame: 1-6 weeks]
metabolic and hormonal profile [Time Frame: 1-6 weeks]
Regional left ventricular function [Time Frame: 1-6 weeks]
Secondary ID(s)
M20090230
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Danish Heart Foundation
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history